Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025
Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation
Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates
Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces its participation and presentation in a series of forthcoming high-profile healthcare conferences.
